Global Blood Therapeutics Rises on Solid Mid-Stage Results
Shares of Global Blood Therapeutics saw a handy gain going into the weekend following positive results from its mid-stage clinical trial.
Health and Healthcare
All Health and Healthcare Articles
Newest first · Page 209
Short Sellers Become More Selective on Major Biotechs
The May 31 short interest data have been compared with the previous report, and short interest moves were mixed in these selected biotech stocks.
Major Pharma Has Short Sellers on the Run
The May 31 short interest data have been compared with the previous figures, and for the selected pharmaceutical stocks short interest was mixed.
Jaguar Animal Health Skyrockets on Stock Purchase Agreement
Jaguar Animal Health shares absolutely skyrocketed in Thursday’s session following the announcement of a common stock purchase agreement.
Tactile Systems Releases Tenative Pricing for IPO
Tactile Systems Technology expects to price 4 million shares within the range of $14 to $16 per share in an initial public offering valued up to more than $73 million.
Do Analysts See an Inflection Point in Valeant Pharmaceuticals After Earnings?
Despite its track record, some analysts are calling for an inflection point, while others are taking a relatively neutral stance on Valeant Pharmaceuticals.
Flexion Therapeutics Raises More Capital in Secondary Offering
Shares of Flexion Therapeutics dropped early on Wednesday following the announcement of an underwritten public offering.
Why the Zimmer Biomet and LDR Deal Is a Big Win
Shares of LDR skyrocketed in Tuesday's session following the definitive agreement for Zimmer Biomet to acquire the company for $1 billion.
Biogen Stumbles Over Missed Mid-Stage Results
Shares of Biogen slumped early in Tuesday's session following the release of less-than-favorable top-line results from its mid-stage clinical study evaluating opicinumab.
Why Earnings Were Not the Biggest Disappointment in Valeant’s Report
Valeant Pharmaceuticals International reported disappointing first-quarter financial results before the markets opened on Tuesday.
Why Analysts Are Still All Over the Place on Sarepta After FDA News
Sarepta Therapeutics Inc. (NASDAQ: SRPT) has seen more than its fair share of volatility in the market of late. Now shares are surging after it has reached a compromise with the U.S. Food and Drug…
How Credit Suisse Views Major Pharma After ASCO
The ASCO annual meeting is absolutely making waves in the pharmaceutical industry. As a result, analysts are giving their two cents on companies making presentations at the conference.
The 5 Biggest Biotech and Pharma Losers From ASCO
Some call the ASCO annual meeting the "Super Bowl for biotechs" because of the significance it holds for so many companies.
Why ProNAi Could Be the Biggest Loser at ASCO
The annual meeting for ASCO is generally one of the biggest weeks of the year for the health care sector. However, there are inevitably winners and losers.
2 Analyst Biotech Stock Calls With Over 100% Upside Potential
The analysts at Wedbush focus in on two biotech companies that not only have data that could prove to be huge, but shares of each have been absolutely hammered over the past year,